S&P 500   5,130.17 (+0.67%)
DOW   39,052.91 (+0.14%)
QQQ   445.05 (+1.38%)
AAPL   178.69 (-1.14%)
MSFT   414.93 (+0.31%)
META   501.98 (+2.42%)
GOOGL   138.16 (-0.22%)
AMZN   178.37 (+0.91%)
TSLA   204.33 (+1.21%)
NVDA   817.54 (+3.34%)
NIO   5.83 (+1.39%)
AMD   200.46 (+4.12%)
BABA   74.88 (+1.15%)
T   16.97 (+0.24%)
F   12.45 (+0.08%)
MU   95.68 (+5.60%)
CGC   3.26 (-0.91%)
GE   159.13 (+1.43%)
DIS   111.95 (+0.33%)
AMC   4.39 (+1.62%)
PFE   26.57 (+0.04%)
PYPL   60.64 (+0.50%)
XOM   105.87 (+1.29%)
S&P 500   5,130.17 (+0.67%)
DOW   39,052.91 (+0.14%)
QQQ   445.05 (+1.38%)
AAPL   178.69 (-1.14%)
MSFT   414.93 (+0.31%)
META   501.98 (+2.42%)
GOOGL   138.16 (-0.22%)
AMZN   178.37 (+0.91%)
TSLA   204.33 (+1.21%)
NVDA   817.54 (+3.34%)
NIO   5.83 (+1.39%)
AMD   200.46 (+4.12%)
BABA   74.88 (+1.15%)
T   16.97 (+0.24%)
F   12.45 (+0.08%)
MU   95.68 (+5.60%)
CGC   3.26 (-0.91%)
GE   159.13 (+1.43%)
DIS   111.95 (+0.33%)
AMC   4.39 (+1.62%)
PFE   26.57 (+0.04%)
PYPL   60.64 (+0.50%)
XOM   105.87 (+1.29%)
S&P 500   5,130.17 (+0.67%)
DOW   39,052.91 (+0.14%)
QQQ   445.05 (+1.38%)
AAPL   178.69 (-1.14%)
MSFT   414.93 (+0.31%)
META   501.98 (+2.42%)
GOOGL   138.16 (-0.22%)
AMZN   178.37 (+0.91%)
TSLA   204.33 (+1.21%)
NVDA   817.54 (+3.34%)
NIO   5.83 (+1.39%)
AMD   200.46 (+4.12%)
BABA   74.88 (+1.15%)
T   16.97 (+0.24%)
F   12.45 (+0.08%)
MU   95.68 (+5.60%)
CGC   3.26 (-0.91%)
GE   159.13 (+1.43%)
DIS   111.95 (+0.33%)
AMC   4.39 (+1.62%)
PFE   26.57 (+0.04%)
PYPL   60.64 (+0.50%)
XOM   105.87 (+1.29%)
S&P 500   5,130.17 (+0.67%)
DOW   39,052.91 (+0.14%)
QQQ   445.05 (+1.38%)
AAPL   178.69 (-1.14%)
MSFT   414.93 (+0.31%)
META   501.98 (+2.42%)
GOOGL   138.16 (-0.22%)
AMZN   178.37 (+0.91%)
TSLA   204.33 (+1.21%)
NVDA   817.54 (+3.34%)
NIO   5.83 (+1.39%)
AMD   200.46 (+4.12%)
BABA   74.88 (+1.15%)
T   16.97 (+0.24%)
F   12.45 (+0.08%)
MU   95.68 (+5.60%)
CGC   3.26 (-0.91%)
GE   159.13 (+1.43%)
DIS   111.95 (+0.33%)
AMC   4.39 (+1.62%)
PFE   26.57 (+0.04%)
PYPL   60.64 (+0.50%)
XOM   105.87 (+1.29%)
NASDAQ:TGTX

TG Therapeutics (TGTX) Stock Price, News & Analysis

$17.97
+0.75 (+4.36%)
(As of 01:28 PM ET)
Today's Range
$17.43
$18.38
50-Day Range
$13.02
$21.30
52-Week Range
$6.46
$35.67
Volume
3.09 million shs
Average Volume
5.27 million shs
Market Capitalization
$2.72 billion
P/E Ratio
898.95
Dividend Yield
N/A
Price Target
$26.17

TG Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
43.9% Upside
$26.17 Price Target
Short Interest
Bearish
26.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.46
Upright™ Environmental Score
News Sentiment
0.67mentions of TG Therapeutics in the last 14 days
Based on 51 Articles This Week
Insider Trading
Selling Shares
$1.14 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.11) to $0.56 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.76 out of 5 stars

Medical Sector

346th out of 957 stocks

Pharmaceutical Preparations Industry

161st out of 440 stocks


TGTX stock logo

About TG Therapeutics Stock (NASDAQ:TGTX)

TG Therapeutics Inc is a biopharmaceutical company that develops and commercializes innovative treatments for multiple sclerosis (MS) and other autoimmune diseases. The company, founded in 2012, is headquartered in New York City and has operations in the United States and Europe. The company aims to provide new and effective therapies to patients with unmet medical needs.

TG Therapeutics has made significant achievements since its inception but has also experienced significant setbacks. The company initially rose to fame by producing the cancer drug Ukoniq which was later pulled from the market due to its ineffectiveness. The company shifted focus and received FDA approvals for a multiple sclerosis drug, Briumvi, for relapsing forms of multiple sclerosis. Additionally, the company conducts extensive clinical trials for other product candidates. These product candidates can potentially provide new treatment options for patients with B-cell malignancies and autoimmune diseases.

TG Therapeutics has a talented and experienced management team dedicated to advancing the company's mission. The current CEO and co-founder of the company is Michael S. Weiss, who has over 25 years of experience in the biopharmaceutical industry. TG Therapeutics has seen financial growth and decline over the past few years. The company has reported significant losses primarily due to removing Ukoniq from its product line and increased investment in clinical development and research activities. 

TG Therapeutics has seen significant volatility in its stock price over the past few years. In 2021, the stock price increased by over 200% due to positive clinical trial results for its product candidates. However, in 2022, the stock price experienced a sharp decline due to concerns about removing the approved drug Ukoniq from the market, delays in clinical development and increased competition. 

TG Therapeutics operates in the biopharmaceutical industry, characterized by high innovation levels and significant regulatory oversight. The industry is also subject to political and economic pressures, including changes in healthcare policy and pricing pressures from payers.

TG Therapeutics faces competition from other companies developing cancer and autoimmune disease treatments, including large pharmaceutical companies such as Roche and Novartis. However, the company's focus on developing novel therapies for unmet medical needs gives it a competitive advantage.

TG Therapeutics has several growth opportunities in its pipeline. The company is currently developing new product candidates which have the potential to provide new treatment options for patients with MS, B-cell malignancies and autoimmune diseases. Additionally, the company may pursue strategic acquisitions or partnerships to expand its product portfolio and reach new markets.

TG Therapeutics faces risks and challenges that may impact its future growth and success. These include changes in healthcare policy and pricing pressures from payers and increased competition from other companies in the market. Additionally, the company is subject to regulatory oversight and must successfully navigate the clinical development and approval process for its product candidates. Failure to do so may result in delays, increased costs, and potential setbacks for the company.

The company's financial performance is also subject to risks, such as changes in interest rates and the availability of financing. The company's debt levels may limit its ability to invest in research and development. Any significant changes in ownership or management may also disrupt operations and impact the company's growth potential.

Furthermore, the success of TG Therapeutics' product candidates is not guaranteed, and the company may need help demonstrating their safety and efficacy in clinical trials. Failure to obtain regulatory approval for these products or to effectively commercialize them may significantly impact the company's financial performance and market position.

TGTX Stock Price History

TGTX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Q4 2023 TG Therapeutics Inc Earnings Call
Earnings Preview For TG Therapeutics
TG Therapeutics' Briumvi Launched In Europe
TG Therapeutics (NASDAQ:TGTX) Stock Rating Lowered by StockNews.com
See More Headlines
Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/01/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TGTX
Employees
245
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.17
High Stock Price Target
$45.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+52.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-198,340,000.00
Pretax Margin
-13.65%

Debt

Sales & Book Value

Annual Sales
$2.79 million
Book Value
$0.40 per share

Miscellaneous

Free Float
137,480,000
Market Cap
$2.61 billion
Optionable
Optionable
Beta
2.42
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report














TGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell TG Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TGTX shares.
View TGTX analyst ratings
or view top-rated stocks.

What is TG Therapeutics' stock price target for 2024?

6 analysts have issued twelve-month price targets for TG Therapeutics' shares. Their TGTX share price targets range from $13.00 to $45.00. On average, they expect the company's stock price to reach $26.17 in the next year. This suggests a possible upside of 43.9% from the stock's current price.
View analysts price targets for TGTX
or view top-rated stocks among Wall Street analysts.

How have TGTX shares performed in 2024?

TG Therapeutics' stock was trading at $17.08 at the start of the year. Since then, TGTX stock has increased by 6.5% and is now trading at $18.19.
View the best growth stocks for 2024 here
.

When is TG Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our TGTX earnings forecast
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) announced its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.03. The biopharmaceutical company earned $43.97 million during the quarter, compared to analysts' expectations of $40.06 million. TG Therapeutics had a trailing twelve-month return on equity of 16.34% and a net margin of 5.42%. During the same period last year, the company posted ($0.39) EPS.

What ETFs hold TG Therapeutics' stock?

ETFs with the largest weight of TG Therapeutics (NASDAQ:TGTX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE).AdvisorShares Let Bob AI Powered Momentum ETF (LETB).

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.03%), Opaleye Management Inc. (1.46%), Goldman Sachs Group Inc. (1.09%), Northern Trust Corp (0.89%), Nuveen Asset Management LLC (0.89%) and Charles Schwab Investment Management Inc. (0.75%). Insiders that own company stock include Laurence N Charney, Michael S Weiss, Sagar Lonial, Sean A Power and Yann Echelard.
View institutional ownership trends
.

How do I buy shares of TG Therapeutics?

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TGTX) was last updated on 3/1/2024 by MarketBeat.com Staff